Frontier Biotechnologies マネジメント

マネジメント基準チェック /34

Frontier Biotechnologiesの CEO はC. J. Wangで、 Jan2013年に任命され、の在任期間は 11.83年です。は、会社の株式の5.62%を直接所有しており、その価値はCN¥ 168.27M 。経営陣と取締役会の平均在任期間はそれぞれ10.3年と6.5年です。

主要情報

C. J. Wang

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	11.8yrs
CEOの所有権	5.6%
経営陣の平均在職期間	10.3yrs
取締役会の平均在任期間	6.5yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

C. J. Wang (66 yo)

11.8yrs

在職期間

CN¥2,228,000

報酬

Dr. Changjin Wang, also known as C. J., Ph D., serves as Chief Executive Officer and Director at Frontier Biotechnologies Inc. since January 2013. Dr. Wang served as Vice President of Business Development...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Qi Shao	Senior VP & CFO	8.8yrs	CN¥1.37m	データなし
Rongjian Lu	CTO & Director	11.8yrs	CN¥1.88m	5.8% CN¥ 173.7m
Yuting Zhu	Supervisor & Deputy GM Administrative Director	no data	CN¥593.80k	データなし
Hangzhou Lv	Senior Vice President of Marketing & Sales	no data	CN¥1.22m	データなし
Qianya Gao	Deputy GM & Secretary of the Board of Directors	3.9yrs	CN¥962.00k	データなし
Dong Xie	Founder	11.8yrs	CN¥2.26m	3.72% CN¥ 111.2m
Changjin Wang	MD, CEO & Director	11.8yrs	CN¥2.23m	5.62% CN¥ 168.3m
Xiao Zheng	Chief Operating Officer	3.7yrs	CN¥3.47m	データなし
Michael Hu	C.M.O.	no data	データなし	データなし

10.3yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: 688221の経営陣は経験豊富で経験豊富です（平均在職期間は10.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Rongjian Lu	CTO & Director	11.8yrs	CN¥1.88m	5.8% CN¥ 173.7m
Yuting Zhu	Supervisor & Deputy GM Administrative Director	5.8yrs	CN¥593.80k	データなし
Dong Xie	Founder	11.8yrs	CN¥2.26m	3.72% CN¥ 111.2m
Changjin Wang	MD, CEO & Director	11.8yrs	CN¥2.23m	5.62% CN¥ 168.3m
Chi Kit Ng	Independent Director	5.8yrs	CN¥150.00k	データなし
Yuantao Cao	Supervisor	6.5yrs	データなし	データなし
Guangji Wang	Independent Director	2.5yrs	CN¥130.20k	データなし
Kai Chen	Independent Director	5.8yrs	CN¥90.70k	データなし
Zhi Zhong Jiang	Chairman of the Supervisory Board & Purchasing Director	8.8yrs	CN¥380.60k	データなし

6.5yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: 688221の取締役会は経験豊富であると考えられます ( 6.5年の平均在任期間)。

Frontier Biotechnologies マネジメント

マネジメント基準チェック /34

主要情報

経営陣の近況

Frontier Biotechnologies Inc., Annual General Meeting, Apr 25, 2024

Recent updates

Third quarter 2024 earnings released: CN¥0.089 loss per share (vs CN¥0.19 loss in 3Q 2023)

Frontier Biotechnologies Inc. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.26 loss in 2Q 2023)

Frontier Biotechnologies Inc. to Report First Half, 2024 Results on Aug 31, 2024

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Frontier Biotechnologies Inc., Annual General Meeting, Apr 25, 2024

Frontier Biotechnologies Inc. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Third quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.29 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.26 loss per share (vs CN¥0.18 loss in 2Q 2022)

Frontier Biotechnologies Inc. to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.16 loss in 1Q 2022)

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Frontier Biotechnologies Announces Positive Phase 1 Results of Its First Coronavirus Main Protease (Mpro) Small Molecule Inhibitor, Laying Foundation for the Treatment of Acute and Long COVID

Frontier Biotechnologies Inc. announced that it expects to receive CNY 270.2 million in funding from Jiezheng Investment Group Co., Ltd, UBS Group AG, Guodu Venture Capital Co., Ltd., Nuode Fund Management Co., Ltd., Guizhou Xiehui Property Development Company Limited

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to CN¥22.90

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: CN¥0.23 loss per share (vs CN¥0.23 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.14 loss per share (vs CN¥0.23 loss in 2Q 2020)

Frontier Biotechnologies' First Long-Acting Injectable (Aikening(R)), in A Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients

Full year 2020 earnings released: CN¥0.80 loss per share (vs CN¥0.73 loss in FY 2019)

New 90-day low: CN¥16.16

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

Frontier Biotechnologies マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Frontier Biotechnologies Inc., Annual General Meeting, Apr 25, 2024

Recent updates

Third quarter 2024 earnings released: CN¥0.089 loss per share (vs CN¥0.19 loss in 3Q 2023)

Frontier Biotechnologies Inc. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.26 loss in 2Q 2023)

Frontier Biotechnologies Inc. to Report First Half, 2024 Results on Aug 31, 2024

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Frontier Biotechnologies Inc., Annual General Meeting, Apr 25, 2024

Frontier Biotechnologies Inc. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Third quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.29 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.26 loss per share (vs CN¥0.18 loss in 2Q 2022)

Frontier Biotechnologies Inc. to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.16 loss in 1Q 2022)

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Frontier Biotechnologies Announces Positive Phase 1 Results of Its First Coronavirus Main Protease (Mpro) Small Molecule Inhibitor, Laying Foundation for the Treatment of Acute and Long COVID

Frontier Biotechnologies Inc. announced that it expects to receive CNY 270.2 million in funding from Jiezheng Investment Group Co., Ltd, UBS Group AG, Guodu Venture Capital Co., Ltd., Nuode Fund Management Co., Ltd., Guizhou Xiehui Property Development Company Limited

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to CN¥22.90

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: CN¥0.23 loss per share (vs CN¥0.23 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.14 loss per share (vs CN¥0.23 loss in 2Q 2020)

Frontier Biotechnologies' First Long-Acting Injectable (Aikening(R)), in A Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients

Full year 2020 earnings released: CN¥0.80 loss per share (vs CN¥0.73 loss in FY 2019)

New 90-day low: CN¥16.16

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34